FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 232 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... May 1, 2021 For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target January 3, 2019 Shelter Puppies Got A Private Tour Of The Georgia Aquarium March 31, 2020 Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk... June 18, 2025 Load more HOT NEWS ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21... Husband Moved To Tears After Opening Christmas Gift From Wife Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,... First immunotherapy approved for cervical cancer in England and Scotland
